P. Sapra
Pfizer,
United States
Keywords: cancer nanotechnology tumor targetting
Summary:
This presentation will cover the application of targeted modalities including antibody-drug conjugates (ADCs) and nanoparticles for the treatment of cancer. Barriers to successful delivery and penetration of nanoparticles in tumor tissues and novel strategies to overcome these limitations will be discussed. The application of nanoparticles for delivery of immunotherapy drugs will be covered. Learnings from ADCs in clinical trials and combination strategies of ADCs with immune-oncology drugs including checkpoint inhibitors will be reviewed.